Skip to main content

Table 1 List of symbols

From: Evaluating human papillomavirus vaccination programs in Canada: should provincial healthcare pay for voluntary adult vaccination?

Symbol

Definition

Sample value used

Parameter range

C U

Unvaccinated female children

(state variable)

 

A U

Unvaccinated adult women

(state variable)

 

C V

Vaccinated female children

(state variable)

 

A V

Vaccinated adult women

(state variable)

 

I U

Uninfected adult women

(state variable)

 

I V

Infected adult women

(state variable)

 

M

Uninfected men

(state variable)

 

N

Infected men

(state variable)

 

π W

Rate of appearance of new females

50 per year

0–100

π M

Rate of appearance of new males

50 per year

0–100

ε

Vaccine immunogenicity in female children

98%

75–98%

ε ¯ MathType@MTEF@5@5@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacPC6xNi=xH8viVGI8Gi=hEeeu0xXdbba9frFj0xb9qqpG0dXdb9aspeI8k8fiI+fsY=rqGqVepae9pg0db9vqaiVgFr0xfr=xfr=xc9adbaqaaeGaciGaaiaabeqaaeqabiWaaaGcbaGafqyTduMbaebaaaa@2D94@

Vaccine immunogenicity in adult women

98%

75–98%

p

Proportion of female children vaccinated

77%

0–100%

p ¯ MathType@MTEF@5@5@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacPC6xNi=xH8viVGI8Gi=hEeeu0xXdbba9frFj0xb9qqpG0dXdb9aspeI8k8fiI+fsY=rqGqVepae9pg0db9vqaiVgFr0xfr=xfr=xc9adbaqaaeGaciGaaiaabeqaaeqabiWaaaGcbaGafmiCaaNbaebaaaa@2D56@

Proportion of adult women vaccinated

40%

0–100%

μ C

Mortality rate of children

1/70 years -1

1/140–1/13

μ

Leaving rate of adults

1/10 years-1

1/12–1

α

Rate of progression of female children to sexually activity

1 13 1 / μ years 1 MathType@MTEF@5@5@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacPC6xNi=xH8viVGI8Gi=hEeeu0xXdbba9frFj0xb9qqpG0dXdb9aspeI8k8fiI+fsY=rqGqVepae9pg0db9vqaiVgFr0xfr=xfr=xc9adbaqaaeGaciGaaiaabeqaaeqabiWaaaGcbaqcfa4aaSaaaeaacqaIXaqmaeaacqaIXaqmcqaIZaWmcqGHsislcqaIXaqmcqGGVaWlcqaH8oqBaaGccqqG5bqEcqqGLbqzcqqGHbqycqqGYbGCcqqGZbWCdaahaaWcbeqaaiabgkHiTiabigdaXaaaaaa@3CBF@

1/12–1

c

Attentuation constant

0.15 years-1

0–0.3

γ

Maximal possible rate of adult vaccination

0.1

0–0.2

f ( ε ¯ p ¯ ) MathType@MTEF@5@5@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacPC6xNi=xH8viVGI8Gi=hEeeu0xXdbba9frFj0xb9qqpG0dXdb9aspeI8k8fiI+fsY=rqGqVepae9pg0db9vqaiVgFr0xfr=xfr=xc9adbaqaaeGaciGaaiaabeqaaeqabiWaaaGcbaGaemOzayMaeiikaGIafqyTduMbaebacuWGWbaCgaqeaiabcMcaPaaa@321C@

Rate at which unvaccinated adult women are vaccinated

c ε ¯ p ¯ 1 ε ¯ p ¯ + γ MathType@MTEF@5@5@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacPC6xNi=xH8viVGI8Gi=hEeeu0xXdbba9frFj0xb9qqpG0dXdb9aspeI8k8fiI+fsY=rqGqVepae9pg0db9vqaiVgFr0xfr=xfr=xc9adbaqaaeGaciGaaiaabeqaaeqabiWaaaGcbaqcfa4aaSaaaeaacqWGJbWycuaH1oqzgaqeaiqbdchaWzaaraaabaGaeGymaeJaeyOeI0IafqyTduMbaebacuWGWbaCgaqeaiabgUcaRiabeo7aNbaaaaa@38A8@

 

β N

Probability of infection of a woman by an infected man

0.00056

0–0.00112

β M

Probability of infection of a man by an infected woman

0.0003

0–0.0006

ψ

Vaccine efficacy

95%

85–95%

  1. Sample parameters were chosen so that 1 μ + 1 α = 13 MathType@MTEF@5@5@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacPC6xNi=xH8viVGI8Gi=hEeeu0xXdbba9frFj0xb9qqpG0dXdb9aspeI8k8fiI+fsY=rqGqVepae9pg0db9vqaiVgFr0xfr=xfr=xc9adbaqaaeGaciGaaiaabeqaaeqabiWaaaGcbaqcfa4aaSaaaeaacqaIXaqmaeaacqaH8oqBaaGccqGHRaWkjuaGdaWcaaqaaiabigdaXaqaaiabeg7aHbaakiabg2da9iabigdaXiabiodaZaaa@3626@ (ie the total time between vaccination and leaving was always 13 years), γc -1 = 16.67 (ie the optimum age of vaccination for a perfect vaccine with 100% coverage was 16 years 9 months), β N > β M (ie the transmission probability from men to women was higher than from women to men), the total prevalence without vaccination was 24% and so that the proportion of adult-only vaccination was equal to the proportion of childhood-only vaccination required to eradicate targeted types.